Dr. Robert Ferris on Additional Data for a Phase III Study Regarding Nivolumab in Head and Neck Cancer
Robert Ferris, MD, PhD, discusses the potential impact the CheckMate-141 study could have regarding nivolumab as potential treatment for patients with head and neck cancer.
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the potential impact the CheckMate-141 study could have regarding nivolumab as potential treatment for patients with head and neck cancer.
Ferris says in the phase III trial, patients with cisplatin-refractory head and neck cancer were randomized to either a nivolumab arm or standard chemotherapy arm. Due to a positive endpoint of overall survival in the nivolumab arm, the study was stopped early and its data added immunotherapy as a fourth modality to the treatment landscape of head and neck cancer, Ferris says.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More
